Award-winning programme continues to make a difference to asthmatic patients
A collaboration between Hull Universities Teaching Hospitals and AstraZeneca has revolutionised the care of asthmatic patients delivering improvements in care for thousands of people with uncontrolled asthma . Approximately 23,000 patients in Yorkshire have poorly controlled asthma and would benefit from further review by clinicians . Most asthma suffers rely heavily on the use of blue inhalers , which is associated with a much higher risk of asthma attacks and hospitalisation . Blue inhaler prescribing has also a negative impact on our environment .
SENTINEL PLUS is an award-winning programme that helps to improve asthma care by reducing the reliance on blue inhalers , a type of inhaler that helps to temporarily relieve the symptoms of asthma .
We have played an instrumental role in SENTINEL PLUS becoming part of the regional AAC Rapid Uptake Products programme and supporting its adoption across all six Primary Care Networks ( PCNs ) in Hull and East Riding – in total 44,275 fewer blue inhalers have been prescribed in a region with some of the highest usage rates in the country .
We also organised several events that brought together more than 400 healthcare professionals to share best practice and further raise awareness of this programme and the resources available to clinicians . There are now 305 PCNs signed up to SENTINEL PLUS throughout England .
Find out about the SENTINEL programme which treats the underlying inflammation of asthma , while reducing the reliance on and prescribing of blue ‘ reliever ’ inhalers and the greenhouse gas emissions they produce .
The SENTINEL project was highly commended at the HSJ Awards
29 Transforming Lives Through Innovation